Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Mar 24

PMID 30901912

Citations 9

Authors

Chan Uk Heo

Chang-Ik Choi

Affiliations

Soon will be listed here.

Abstract

Precision medicine is a scientific and medical practice for personalized therapy based on patients' individual genetic, environmental, and lifestyle characteristics. Pharmacogenetics and pharmacogenomics are also rapidly developing and expanding as a key element of precision medicine, in which the association between individual genetic variabilities and drug disposition and therapeutic responses are investigated. Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia mainly associated with insulin resistance, with the risk of clinically important cardiovascular, neurological, and renal complications. The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems. In this review article, we summarized current progress on pharmacogenetics of newer second-line antidiabetic medications in clinical practices and discussed their therapeutic implications for precision medicine in T2D management. Several biomarkers associated with drug responses have been identified from extensive clinical pharmacogenetic studies, and functional variations in these genes have been shown to significantly affect drug-related glycemic control, adverse reactions, and risk of diabetic complications. More comprehensive pharmacogenetic research in various clinical settings will clarify the therapeutic implications of these genes, which may be useful tools for precision medicine in the treatment and prevention of T2D and its complications.

Citing Articles

Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.

Eghbali M, Alaei-Shahmiri F, Hashemi-Madani N, Emami Z, Mostafavi L, Malek M Adv Ther. 2024; 41(2):826-836.

PMID: 38172377 DOI: 10.1007/s12325-023-02761-1.

Phytochemical Content and Antidiabetic Properties of Most Commonly Used Antidiabetic Medicinal Plants of Kenya.

Muema F, Nanjala C, Oulo M, Wangchuk P Molecules. 2023; 28(20).

PMID: 37894680 PMC: 10609527. DOI: 10.3390/molecules28207202.

Five-Aminolevulinic Acid (5-ALA) Induces Heme Oxygenase-1 and Ameliorates Palmitic Acid-Induced Endoplasmic Reticulum Stress in Renal Tubules.

Hamada S, Mae Y, Takata T, Hanada H, Kubo M, Taniguchi S Int J Mol Sci. 2023; 24(12).

PMID: 37373300 PMC: 10299457. DOI: 10.3390/ijms241210151.

Comparative evaluation of metformin & sitaformin in classic PCOS patients undergoing intracytoplasmic sperm injection: A randomized controlled pilot study.

Zadeh Modarres S, Daneshjou D, Mehranjani M, Shariatzadeh S Indian J Med Res. 2023; 157(1):66-73.

PMID: 37040229 PMC: 10284353. DOI: 10.4103/ijmr.IJMR_2139_20.

Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?-a comparison between Asian versus White patients.

Scheen A Ann Transl Med. 2023; 10(24):1418.

PMID: 36660673 PMC: 9843340. DOI: 10.21037/atm-2022-54.

References

Greig N, Holloway H, De Ore K, Jani D, Wang Y, Zhou J . Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 1999; 42(1):45-50. DOI: 10.1007/s001250051111. View

Jonas J, Sharma A, Hasenkamp W, Ilkova H, Patane G, Laybutt R . Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem. 1999; 274(20):14112-21. DOI: 10.1074/jbc.274.20.14112. View

Young A, Gedulin B, Bhavsar S, Bodkin N, Jodka C, Hansen B . Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999; 48(5):1026-34. DOI: 10.2337/diabetes.48.5.1026. View

Xu G, Stoffers D, Habener J, Bonner-Weir S . Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999; 48(12):2270-6. DOI: 10.2337/diabetes.48.12.2270. View

Edwards C, Stanley S, Davis R, Brynes A, Frost G, Seal L . Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281(1):E155-61. DOI: 10.1152/ajpendo.2001.281.1.E155. View

Egan J, Clocquet A, Elahi D . The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002; 87(3):1282-90. DOI: 10.1210/jcem.87.3.8337. View

Gloyn A, Weedon M, Owen K, Turner M, Knight B, Hitman G . Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003; 52(2):568-72. DOI: 10.2337/diabetes.52.2.568. View

Meier J, Gallwitz B, Salmen S, Goetze O, Holst J, Schmidt W . Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(6):2719-25. DOI: 10.1210/jc.2003-030049. View

Kolterman O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T . Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(7):3082-9. DOI: 10.1210/jc.2002-021545. View

10.

Fineman M, Bicsak T, Shen L, Taylor K, Gaines E, Varns A . Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003; 26(8):2370-7. DOI: 10.2337/diacare.26.8.2370. View

11.

Eng J, Kleinman W, Singh L, Singh G, Raufman J . Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267(11):7402-5. View

12.

Elrick H, STIMMLER L, HLAD Jr C, Arai Y . PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab. 1964; 24:1076-82. DOI: 10.1210/jcem-24-10-1076. View

13.

Drucker D . Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003; 144(12):5145-8. DOI: 10.1210/en.2003-1147. View

14.

Dimitrakoudis D, Vranic M, Klip A . Effects of hyperglycemia on glucose transporters of the muscle: use of the renal glucose reabsorption inhibitor phlorizin to control glycemia. J Am Soc Nephrol. 1992; 3(5):1078-91. DOI: 10.1681/ASN.V351078. View

15.

Pfutzner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T . Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004; 27(3):682-7. DOI: 10.2337/diacare.27.3.682. View

16.

Brubaker P, Drucker D . Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004; 145(6):2653-9. DOI: 10.1210/en.2004-0015. View

17.

Weber A . Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004; 47(17):4135-41. DOI: 10.1021/jm030628v. View

18.

Degn K, Brock B, Juhl C, Djurhuus C, Grubert J, Kim D . Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004; 53(9):2397-403. DOI: 10.2337/diabetes.53.9.2397. View

19.

Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A . Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract. 2004; 66(1):63-9. DOI: 10.1016/j.diabres.2004.02.004. View

20.

Buse J, Henry R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11):2628-35. DOI: 10.2337/diacare.27.11.2628. View